Last reviewed · How we verify
oxaliplatin, irinotecan, folinic acid, fluorouracil
oxaliplatin, irinotecan, folinic acid, fluorouracil is a Platinum-based chemotherapy Small molecule drug developed by GERCOR - Multidisciplinary Oncology Cooperative Group. It is currently in Phase 3 development for Adjuvant treatment of stage III colon cancer, First-line treatment of metastatic colorectal cancer.
Oxaliplatin, irinotecan, folinic acid, and fluorouracil work together to inhibit thymidylate synthase and DNA synthesis, leading to cell death in rapidly dividing cancer cells.
Oxaliplatin, irinotecan, folinic acid, and fluorouracil work together to inhibit thymidylate synthase and DNA synthesis, leading to cell death in rapidly dividing cancer cells. Used for Adjuvant treatment of stage III colon cancer, First-line treatment of metastatic colorectal cancer.
At a glance
| Generic name | oxaliplatin, irinotecan, folinic acid, fluorouracil |
|---|---|
| Sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group |
| Drug class | Platinum-based chemotherapy |
| Target | Thymidylate synthase, topoisomerase I |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Oxaliplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, causing DNA damage and apoptosis in cancer cells. Irinotecan is a topoisomerase I inhibitor that prevents DNA replication and repair, while folinic acid (leucovorin) enhances the effectiveness of fluorouracil by stabilizing the ternary complex of thymidylate synthase, fluorouracil, and folate. Fluorouracil is a thymidylate synthase inhibitor that blocks DNA synthesis and repair, leading to cell death.
Approved indications
- Adjuvant treatment of stage III colon cancer
- First-line treatment of metastatic colorectal cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea and vomiting
- Fatigue
- Anemia
Key clinical trials
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer (PHASE2)
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer (PHASE3)
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2, PHASE3)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (PHASE3)
- Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer (PHASE2, PHASE3)
- A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxaliplatin, irinotecan, folinic acid, fluorouracil CI brief — competitive landscape report
- oxaliplatin, irinotecan, folinic acid, fluorouracil updates RSS · CI watch RSS
- GERCOR - Multidisciplinary Oncology Cooperative Group portfolio CI
Frequently asked questions about oxaliplatin, irinotecan, folinic acid, fluorouracil
What is oxaliplatin, irinotecan, folinic acid, fluorouracil?
How does oxaliplatin, irinotecan, folinic acid, fluorouracil work?
What is oxaliplatin, irinotecan, folinic acid, fluorouracil used for?
Who makes oxaliplatin, irinotecan, folinic acid, fluorouracil?
What drug class is oxaliplatin, irinotecan, folinic acid, fluorouracil in?
What development phase is oxaliplatin, irinotecan, folinic acid, fluorouracil in?
What are the side effects of oxaliplatin, irinotecan, folinic acid, fluorouracil?
What does oxaliplatin, irinotecan, folinic acid, fluorouracil target?
Related
- Drug class: All Platinum-based chemotherapy drugs
- Target: All drugs targeting Thymidylate synthase, topoisomerase I
- Manufacturer: GERCOR - Multidisciplinary Oncology Cooperative Group — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of stage III colon cancer
- Indication: Drugs for First-line treatment of metastatic colorectal cancer
- Compare: oxaliplatin, irinotecan, folinic acid, fluorouracil vs similar drugs
- Pricing: oxaliplatin, irinotecan, folinic acid, fluorouracil cost, discount & access